FASgen Diagnostics

FASgen is a biotechnology company focused on the development of therapeutic and diagnostic products targeting Fatty Acid Synthase (FAS). Founded by researchers from Johns Hopkins University, the company leverages the discovery that FAS is significantly overexpressed in many human cancers and plays a key role in metabolic regulation. Their pipeline includes small molecule inhibitors designed to treat various solid tumors and obesity by modulating fatty acid synthesis. Additionally, FASgen develops diagnostic tools to identify FAS expression in clinical samples, serving as a potential prognostic marker for cancer progression. The company's technology aims to exploit the unique metabolic requirements of cancer cells to provide targeted treatment options.